Concepedia

NEWEST: a Phase II, randomised, neoadjuvant trial comparing fulvestrant 500 mg vs 250 mg in postmenopausal women with locally advanced, oestrogen receptor-positive (ER+) breast cancer

CF Singer, Irene Kuter, R. Hegg, R. Badwe, Nadia Harbeck, José Bines, Elyse E. Lowe

European Journal of Cancer Supplements · 2008 · 16 citations · 0 references

DOI

Concepts